In the current study, it was also found that anlotinib can mediate the JAK2/STAT3/VEGFA signaling pathway in glioma cells to decrease levels of secretory VEGFA and angiogenesis, and in combination with TMZ, the anti-angiogenesis and cytotoxic effects of anlotinib are improved. The gene discussed is STAT3; the disease is central nervous system cancer.